This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Aralez Pharmaceuticals Inc.

Drug Names(s): metoprolol succinate, Seloken

Description: TOPROL-XL is a beta1-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended release tablets. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, andmembrane-stabilizing activity is detectable only at plasma concentrations much greaterthan required for beta-blockade. Beta blockers block the action of epinephrine and norepinephrine. As a result, they slow the heart rate, and slow conduction through the AV node between the atria and ventricles of the heart.

Deal Structure: Aralez and AstraZeneca
In October 2016, Aralez Pharmaceuticals announced it will acquire the U.S. rights to Toprol-XL (metoprolol succinate) and its Authorized Generic (AG) pursuant to an agreement entered into between AstraZeneca and Aralez Pharmaceuticals. The agreement includes an initial upfront payment of $175 million, which will be financed through a previously committed senior secured debt facility with Deerfield Management. At closing, Aralez will also borrow funds under this credit facility to replenish $25 million that was paid from cash on hand in connection with the recently announced ZONTIVITY acquisition. In addition, Deerfield has agreed to provide Aralez access to up to an additional $250 million in capital to fund future mutually agreeable acquisitions. The transaction with AstraZeneca also includes mid-teen percentage royalties and up to $48 million of potential contingent milestone payments. In connection with the Asset Purchase Agreement, at closing the...See full deal structure in Biomedtracker

Partners: AstraZeneca PLC

Toprol-XL News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug